Table 1.

Oncolytic Herpes viruses tested in oncology clinical trials to date.

Virus Strain	Modifications	Aim
G207	insertion of the Escherichia coli lacZ sequence at ICP6/UL39	reducing ribonucleotide reductase activity [14]
	deletion of γ34.5/RL1	reducing neurovirulence [15]
1716	deletion of γ34.5/RL1	reducing neurovirulence [15]
HF10	deletion in the Bam HI-B fragment	unknown
	two incomplete UL56 copies without promoter	possibly reducing neurovirulence [16]
	reduced expression of UL43, UL49.5, UL55, LAT	possible influence on immunogenicity (UL43), unknown (UL49.5), reduced virus reactivation (LAT) [17]
	increased expression of UL53 and UL54	reduced viral shedding (UL53) [17]
NV1020	deletion of one allele of α0, α4, γ34.5 and UL56	reducing infectivity, viral replication and neuroinvasiveness [18]
Talimogene laherparepvec (T-Vec)	deletion of ICP34.5	reducing neurovirulence [15]
	deletion of ICP47	augment immune response [19]
	insertion of GM-CSF gene	augment immune response [19]